MedTrace Logo

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

NCT00761215 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2019-11-25

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.

Conditions

  • Skin Diseases, Infectious
  • Skin Diseases, Bacterial

Interventions

DRUG

TR-701 200 mg

oral TR-701 200 mg for 5 to 7 days

DRUG

TR-701 300 mg

oral TR-701 300 mg for 5 to 7 days

DRUG

TR-701 400 mg

TR-701 400 mg for 5 to 7 days

Sponsors & Collaborators

  • Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Principal Investigators

  • Philippe Prokocimer, MD · Trius

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-17
Primary Completion
2009-02-24
Completion
2009-02-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761215 on ClinicalTrials.gov